Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer
- PMID: 16683009
- DOI: 10.1038/sj.pcan.4500879
Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer
Abstract
Most malignancies have increased glycolysis for energy requirement of rapid cell proliferation, which is the basis for tumor imaging through glucose analog FDG (2-deoxy-2-fluoro-D-glucose) with positron emission tomography. One of significant characteristics of prostate cancer is slow glycolysis and low FDG avidity. Recent studies showed that prostate cancer is associated with changes of fatty acid metabolism. Several enzymes involved in the metabolism of fatty acids have been determined to be altered in prostate cancer relative to normal prostate, which is indicative of an enhanced beta-oxidation pathway in prostate cancer. Increased fatty acid utilization in prostate cancer provides both ATP and acetyl-coenzyme A (CoA); subsequently, increased availability of acetyl-CoA makes acceleration of citrate oxidation possible, which is an important energy source as well. Dominant fatty acid metabolism rather than glycolysis has the potential to be the basis for imaging diagnosis and targeted treatment of prostate cancer.
Similar articles
-
Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer.Prostate. 2005 Jun 1;63(4):316-23. doi: 10.1002/pros.20177. Prostate. 2005. PMID: 15599942
-
Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism.Cancer Res. 2009 Oct 15;69(20):8133-40. doi: 10.1158/0008-5472.CAN-09-0775. Epub 2009 Oct 13. Cancer Res. 2009. PMID: 19826053
-
Fatty acid synthase: a metabolic oncogene in prostate cancer?J Cell Biochem. 2004 Jan 1;91(1):47-53. doi: 10.1002/jcb.10708. J Cell Biochem. 2004. PMID: 14689581 Review.
-
Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents.Diabetes. 2007 Aug;56(8):2085-92. doi: 10.2337/db07-0093. Epub 2007 May 22. Diabetes. 2007. PMID: 17519422
-
Calcidiol and prostate cancer.J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):183-90. doi: 10.1016/j.jsbmb.2004.12.009. Epub 2005 Jan 22. J Steroid Biochem Mol Biol. 2005. PMID: 15860261 Review.
Cited by
-
Innovation in metabolomics to improve personalized healthcare.Ann N Y Acad Sci. 2015 Jun;1346(1):57-62. doi: 10.1111/nyas.12775. Epub 2015 May 26. Ann N Y Acad Sci. 2015. PMID: 26014591 Free PMC article. Review.
-
Association of androgen receptor expression with glucose metabolic features in triple-negative breast cancer.PLoS One. 2022 Sep 30;17(9):e0275279. doi: 10.1371/journal.pone.0275279. eCollection 2022. PLoS One. 2022. PMID: 36178912 Free PMC article.
-
Molecular Changes in Tissue Proteome during Prostate Cancer Development: Proof-of-Principle Investigation.Diagnostics (Basel). 2020 Aug 31;10(9):655. doi: 10.3390/diagnostics10090655. Diagnostics (Basel). 2020. PMID: 32878211 Free PMC article.
-
Targeting valine catabolism to inhibit metabolic reprogramming in prostate cancer.Cell Death Dis. 2024 Jul 18;15(7):513. doi: 10.1038/s41419-024-06893-2. Cell Death Dis. 2024. PMID: 39025852 Free PMC article.
-
Racial differences in distribution of fatty acids in prostate cancer and benign prostatic tissues.Lipids Health Dis. 2019 Nov 3;18(1):189. doi: 10.1186/s12944-019-1130-4. Lipids Health Dis. 2019. PMID: 31677641 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical